Complete Story
06/23/2021
Biosimilars Drive Savings in Medicare’s Oncology Care Model
Medicare value-based care programs are under great scrutiny to ensure that they can drive demonstrable savings and quality improvement. Adoption of higher-value biosimilar drugs by participants in Medicare’s Oncology Care Model (OCM) could drive the pilot program closer to its goal of generating net savings to Medicare. READ MORE
Report Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!